Imprivata Introduces New Advanced Access Management and Passwordless Authentication Capabilities to Enhance Clinical Efficiency, Security, and Essential Eight Compliance




Imprivata Introduces New Advanced Access Management and Passwordless Authentication Capabilities to Enhance Clinical Efficiency, Security, and Essential Eight Compliance

Imprivata Enterprise Access Management now offers facial recognition, AI-powered behavioral analytics, and high-assurance identity verification to further streamline clinical access, improve operational efficiency, and strengthen security posture

MELBOURNE, March 16, 2026 (GLOBE NEWSWIRE) — Imprivata, a leading provider of access management solutions for healthcare and other mission-critical industries, today introduced comprehensive new capabilities designed to help Australian healthcare organisations improve clinical workflow efficiency while strengthening cyber security and compliance with the Australian Cyber Security Centre’s (ACSC) Essential Eight mitigation strategies.

Imprivata Enterprise Access Management (EAM) now offers context-aware passwordless authentication, high-assurance identity verification, and AI-powered behavioral analytics, expanding the company’s leading solutions for supporting fast, frictionless access, stronger security and compliance, and improved operational efficiency.

“As the Australian healthcare market continues to embrace digital transformation, it is critical that care providers have fast, consistent access to the devices, applications, and resources they need to remain focused on delivering high-quality care,” said Fran Rosch, CEO of Imprivata. “Healthcare organisations in Australia continue to rely on Imprivata for this fast, frictionless access, and we are excited to bring innovative new capabilities to market to drive passwordless access and help meet evolving regulatory requirements such as the Essential Eight.”

Addressing Australia’s Essential Eight Requirements

Healthcare delivery continues to evolve rapidly across Australia, with digital transformation efforts aimed at boosting clinician productivity, reducing administrative burden and safeguarding sensitive patient information. At the same time, organisations face heightened expectations to implement robust cyber security controls consistent with the Essential Eight — a set of prioritised mitigation strategies designed to reduce the likelihood and impact of cyber-attack incidents. These strategies include multi-factor authentication (MFA), patching, least-privilege access, application hardening, and regular backups as a baseline for cyber resilience.

The new EAM functionality delivers frictionless, secure access that aligns with the operational realities of clinical environments while meeting key cyber security controls demanded by the Essential Eight:

• Fast, Passwordless Access: Clinicians and care staff gain rapid access to clinical applications, shared workstations and mobile devices, reducing time spent on repetitive logins and password resets — a significant productivity drag in busy healthcare settings.
• Optimised Shared Device Workflows: By streamlining transitions between users on shared workstations, Imprivata reduces disruption in care delivery and supports smoother clinical handovers, enabling clinicians to spend more time on patient-centric tasks rather than IT friction.
• Unified Identity Across Systems: EAM unifies identity and authentication across disparate systems and applications, helping clinicians get seamless, context-appropriate access without compromising security or workflow continuity.
• Robust Multi-Factor Authentication (MFA): MFA is a cornerstone of the Essential Eight strategy and one of the most effective controls to prevent credential compromise and unauthorised access. Imprivata supports strong, phishing-resistant MFA using modern authentication methods — including biometrics, hardware tokens, and standards-based cryptographic factors — helping organisations meet the ASD’s expectations for secure authentication implementations.
• Policy-Driven Access Controls: EAM enforces role-based and contextual access policies that support least-privilege access and help reduce risk exposure in line with Essential Eight-aligned security goals.
• Audit-Ready Reporting: Detailed authentication and access logs help IT and security teams demonstrate control implementation and support maturity assessments against Essential Eight requirements.

Interested in learning more?
Imprivata offers several different ways to learn more about Imprivata EAM and the expanded functionality:

• Register here to attend our annual customer event: Imprivata Connect Sydney 2026
• Watch our on-demand webinar for a first look at the new features
• Request a demo here to see the solution in action here.

About Imprivata 
Imprivata delivers simple and secure access management solutions for healthcare and other mission-critical industries to ensure every second of crucial work is both frictionless and secure. Imprivata’s platform of innovative, interoperable access management and privileged access security solutions enable organisations to fully manage and secure all enterprise and third-party identities to facilitate seamless user access, protect against internal and external security threats, and reduce total cost of ownership. For more information, visit www.imprivata.com.    
 
Media Contact 
press@imprivata.com  

CMR Surgical Advances Physical AI to Support the Future of Robotic Surgery with NVIDIA




CMR Surgical Advances Physical AI to Support the Future of Robotic Surgery with NVIDIA

Cambridge-based surgical robotics company contributes majority of surgical data to world’s largest open healthcare robotics dataset

Cambridge, UK and San Jose, California – 16 March 2026, CMR Surgical (“CMR”), the global surgical robotics company, today announced its participation in NVIDIA’s Physical AI healthcare robotics initiative, unveiled at NVIDIA GTC. As part of the initiative, CMR contributed the majority of surgical data used to create Open-H — the world’s largest open dataset for healthcare robotics — designed to train the next generation of intelligent surgical systems.

The dataset combines real-world surgical video, robotic telemetry and multimodal data from leading healthcare and robotics organisations. CMR contributed close to 500 hours anonymised surgical data from its Versius Surgical Robotic System, representing the largest share of surgical data in the initiative.

Open‑H underpins Isaac GR00T‑H, the first open vision‑language‑action model for healthcare robotics, designed to enable robotic systems to better interpret complex surgical environments and tasks. These technologies aim to accelerate the development of intelligent robotic systems while maintaining the rigorous safety and clinical oversight required in healthcare.

Building the Foundations of Physical AI in Surgery

Robotic surgery has already enabled millions of minimally invasive procedures worldwide, helping surgeons perform complex operations with greater precision and control. However, advancing surgical robotics further requires new approaches to how robotic systems learn from clinical experience.

With NVIDIA Physical AI infrastructure the ecosystem has a platform that allows robotic systems to be trained and evaluated in simulated environments before deployment, helping accelerate development while maintaining high safety standards.

CMR is contributing real-world surgical data to the effort and is also using NVIDIA Cosmos-H to generate physically accurate synthetic surgical data and evaluate new robotic policies for the future development of the Versius platform.

Enhancing Surgeon Capabilities Through Data and AI

CMR designed Versius as a digitally enabled surgical platform capable of capturing meaningful surgical data during procedures. By contributing anonymised data to initiatives such as Open‑H, the company aims to support broader innovation across the healthcare robotics community.

In the future, Physical AI technologies could enable surgical systems to better understand surgical workflows, assist surgeons with complex tasks and support advanced training and simulation environments. This can help democratise access to minimally invasive surgery and ultimately close the gap of five billion people globally who lack access to safe and affordable surgery.

These technologies are designed to augment surgical expertise, helping clinicians deliver high-quality care more consistently and efficiently. As healthcare systems worldwide face increasing surgical demand and workforce constraints, innovations that enhance surgeon capabilities may also help expand access to minimally invasive procedures for more patients.

Chris Fryer, Chief Technology Officer at CMR Surgical, commented: “Surgical robotics generates a rich understanding of how procedures are performed. By contributing real‑world surgical data to collaborative initiatives like Open‑H, we are helping build the foundations for the next generation of intelligent surgical systems. Because Versius is the most software-driven robot on the market, we were well-placed to share our data with the wider ecosystem.

Our focus is on technologies that support surgeons and expand access to minimally invasive surgery. Combining clinical data with advances in AI and simulation creates a powerful opportunity to accelerate innovation responsibly.”

David Niewolny, Head of Business Development for Healthcare and Medical Technology at NVIDIA said: “The next generation of surgical robotics will be powered by data, simulation and AI working together. By responsibly contributing surgical data and training open models on NVIDIA’s physical AI platform, medical technology leaders like CMR Surgical are accelerating a new generation of intelligent robotic systems that can assist surgeons, scale surgical expertise and ultimately expand access to high-quality care.”

Media Contacts: If you wish to see more, please contact CMR Surgical at:
Press Office, CMR Surgical
E pressoffice@cmrsurgical.com

Notes to editors:

The Versius Surgical Robotic System

The Versius Surgical Robotic System is designed to support surgeons in performing minimally invasive procedures across a range of specialties.

Versius features a modular, portable design that integrates into existing operating room environments and surgical workflows. Its open console design allows surgeons to communicate easily with the operating team while maintaining ergonomic control of the system.

Through its wider digital ecosystem — including surgical video, robotic telemetry and clinical data — Versius captures insights that support continuous learning and surgical innovation.

About CMR Surgical Limited

CMR Surgical (CMR) is a global medical devices company dedicated to transforming surgery with Versius, a next-generation surgical robot.

Headquartered in Cambridge, United Kingdom, CMR is committed to working with surgeons, surgical teams and hospital partners, to provide an optimal tool to make robotic minimally invasive surgery universally accessible and affordable. With Versius, we are on a mission to redefine the surgical robotics market with practical, innovative technology and data that can improve surgical care.

Founded in 2014, CMR Surgical is a private limited company backed by an international shareholder base.

CMR Surgical Advances Physical AI to Support the Future of Robotic Surgery with NVIDIA




CMR Surgical Advances Physical AI to Support the Future of Robotic Surgery with NVIDIA

Cambridge-based surgical robotics company contributes majority of surgical data to world’s largest open healthcare robotics dataset

Cambridge, UK and San Jose, California – 16 March 2026, CMR Surgical (“CMR”), the global surgical robotics company, today announced its participation in NVIDIA’s Physical AI healthcare robotics initiative, unveiled at NVIDIA GTC. As part of the initiative, CMR contributed the majority of surgical data used to create Open-H — the world’s largest open dataset for healthcare robotics — designed to train the next generation of intelligent surgical systems.

The dataset combines real-world surgical video, robotic telemetry and multimodal data from leading healthcare and robotics organisations. CMR contributed close to 500 hours anonymised surgical data from its Versius Surgical Robotic System, representing the largest share of surgical data in the initiative.

Open‑H underpins Isaac GR00T‑H, the first open vision‑language‑action model for healthcare robotics, designed to enable robotic systems to better interpret complex surgical environments and tasks. These technologies aim to accelerate the development of intelligent robotic systems while maintaining the rigorous safety and clinical oversight required in healthcare.

Building the Foundations of Physical AI in Surgery

Robotic surgery has already enabled millions of minimally invasive procedures worldwide, helping surgeons perform complex operations with greater precision and control. However, advancing surgical robotics further requires new approaches to how robotic systems learn from clinical experience.

With NVIDIA Physical AI infrastructure the ecosystem has a platform that allows robotic systems to be trained and evaluated in simulated environments before deployment, helping accelerate development while maintaining high safety standards.

CMR is contributing real-world surgical data to the effort and is also using NVIDIA Cosmos-H to generate physically accurate synthetic surgical data and evaluate new robotic policies for the future development of the Versius platform.

Enhancing Surgeon Capabilities Through Data and AI

CMR designed Versius as a digitally enabled surgical platform capable of capturing meaningful surgical data during procedures. By contributing anonymised data to initiatives such as Open‑H, the company aims to support broader innovation across the healthcare robotics community.

In the future, Physical AI technologies could enable surgical systems to better understand surgical workflows, assist surgeons with complex tasks and support advanced training and simulation environments. This can help democratise access to minimally invasive surgery and ultimately close the gap of five billion people globally who lack access to safe and affordable surgery.

These technologies are designed to augment surgical expertise, helping clinicians deliver high-quality care more consistently and efficiently. As healthcare systems worldwide face increasing surgical demand and workforce constraints, innovations that enhance surgeon capabilities may also help expand access to minimally invasive procedures for more patients.

Chris Fryer, Chief Technology Officer at CMR Surgical, commented: “Surgical robotics generates a rich understanding of how procedures are performed. By contributing real‑world surgical data to collaborative initiatives like Open‑H, we are helping build the foundations for the next generation of intelligent surgical systems. Because Versius is the most software-driven robot on the market, we were well-placed to share our data with the wider ecosystem.

Our focus is on technologies that support surgeons and expand access to minimally invasive surgery. Combining clinical data with advances in AI and simulation creates a powerful opportunity to accelerate innovation responsibly.”

David Niewolny, Head of Business Development for Healthcare and Medical Technology at NVIDIA said: “The next generation of surgical robotics will be powered by data, simulation and AI working together. By responsibly contributing surgical data and training open models on NVIDIA’s physical AI platform, medical technology leaders like CMR Surgical are accelerating a new generation of intelligent robotic systems that can assist surgeons, scale surgical expertise and ultimately expand access to high-quality care.”

Media Contacts: If you wish to see more, please contact CMR Surgical at:
Press Office, CMR Surgical
E pressoffice@cmrsurgical.com

Notes to editors:

The Versius Surgical Robotic System

The Versius Surgical Robotic System is designed to support surgeons in performing minimally invasive procedures across a range of specialties.

Versius features a modular, portable design that integrates into existing operating room environments and surgical workflows. Its open console design allows surgeons to communicate easily with the operating team while maintaining ergonomic control of the system.

Through its wider digital ecosystem — including surgical video, robotic telemetry and clinical data — Versius captures insights that support continuous learning and surgical innovation.

About CMR Surgical Limited

CMR Surgical (CMR) is a global medical devices company dedicated to transforming surgery with Versius, a next-generation surgical robot.

Headquartered in Cambridge, United Kingdom, CMR is committed to working with surgeons, surgical teams and hospital partners, to provide an optimal tool to make robotic minimally invasive surgery universally accessible and affordable. With Versius, we are on a mission to redefine the surgical robotics market with practical, innovative technology and data that can improve surgical care.

Founded in 2014, CMR Surgical is a private limited company backed by an international shareholder base.

LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC




LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC

Company to Report Fourth Quarter Financial Results and Provide Strategic Update on March 31, 2026

ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) — LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, announced that it reached an agreement with Alcon Research, LLC (“Alcon”) to terminate the merger agreement between the parties.

We understand that the Federal Trade Commission intends to seek to enjoin the acquisition contemplated by the merger agreement. The Company and Alcon mutually agreed that terminating the merger agreement at this time is in the best interest of both companies, as the required closing condition of receiving necessary U.S. regulatory approvals is unlikely to be met by the merger agreement’s outside date of April 23, 2026 or the potential extended outside date of July 23, 2026. The Company will retain the $10.0 million deposit contemplated by the merger agreement.

“While we are disappointed with this outcome and the FTC’s intention to challenge the proposed transaction, we remain committed to advancing the field of cataract surgery through the continued market growth of our ALLY Robotic Cataract Laser System™. Since its commercial introduction in 2022, we believe it has become clearer every day that ALLY is the future of refractive cataract surgery. With ALLY, we were able to significantly extend our technology leadership position, established on the strength of our previous-generation LLS platform. We have expanded our footprint and LENSAR’s influence in the space, which supported market share gains and significant procedure growth. Our team is committed to realizing the full potential of our innovation and capturing the significant untapped opportunity that exists in the market we serve,” said Nick Curtis, President and CEO of LENSAR. “We are focused on continuing to drive the expansion of ALLY’s global installed base and procedure volumes, and creating long-term value for patients, our surgeon partners and shareholders. We will share more detail on our strategy when we release our financial results on March 31, 2026.”

Additional Information:

LENSAR plans to report fourth quarter and full-year 2025 financial results and additional details on its go-forward strategy on Tuesday, March 31, 2026, with a press release to be issued prior to the open of trading. The Company will host a conference call on March 31 at 8:30 a.m. Eastern Time. Details on how to access the conference call will be provided in an upcoming announcement.

About LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary
Streamline® software technology, designed to guide surgeons to achieve better outcomes.

Forward-looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “aim,” “anticipate,” “approach,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “goal,” “intend,” “look,” “may,” “mission,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “should,” “target,” “will,” “would,” or the negative thereof and similar words and expressions.

Forward-looking statements are based on management’s current expectations, beliefs and assumptions and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: (i) risks related to disruption of management time from ongoing business operations due to the terminated merger with Alcon (the “Terminated Merger”); (ii) the risk that any announcements relating to the Terminated Merger could have adverse effects on the market price of the Company’s common stock; (iii) the significant costs, expenses and fees for professional services and other transaction costs in connection with the Terminated Merger and the risk that the deposit from Alcon retained by the Company is insufficient to cover such costs, expenses and fees; (iv) the risk of any litigation related to the Terminated Merger; (v) the risk that the Terminated Merger could have an adverse effect on the ability of the Company to retain and maintain relationships with customers, suppliers and other business partners and retain and hire key personnel and on its operating results and business generally; (vi) the risks inherent in Company’s ability to grow its business; and (vii) the Company’s ability to obtain financing on favorable terms, or at all. In addition, a number of other important factors could cause the Company’s actual future results and other future circumstances to differ materially from those expressed in any forward-looking statements, including but not limited to the other important factors that are disclosed under the heading “Risk Factors” contained in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in its other filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, to be filed with the SEC, each accessible on the SEC’s website at www.sec.gov and the Investor Relations section of the Company’s website at https://ir.lensar.com.

All forward-looking statements are expressly qualified in their entirety by such factors. Except as required by law, the Company undertakes no obligation to publicly update or review any forward-looking statement, whether because of new information, future developments or otherwise. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Source: LENSAR, Inc.

Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions




Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions

• With the addition of 2,176 NVIDIA Blackwell GPUs, Roche now operates the pharmaceutical industry’s largest announced hybrid-cloud AI factory, totaling more than 3,500 GPUs.
• The new computational infrastructure supports Roche’s vision of building an AI-accelerated healthcare organisation.
• NVIDIA AI factories help accelerate discoveries, enable more efficient clinical trials, and unlock data insights at scale, ultimately advancing innovation and improved healthcare outcomes.

Basel, 16 March 2026 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that an expansion of its global AI infrastructure, deploying a large-scale AI factory powered by a full stack of the latest-generation NVIDIA accelerated computing and AI. Featuring 2,176 high-performance GPUs on premises across the United States and Europe and embedded across the entire value chain, this infrastructure is designed to accelerate the development of diagnostics solutions and therapeutics. With this most recent investment, Roche’s combined on-premise and cloud GPU infrastructure now exceeds 3,500 Blackwell GPUs, which is the greatest announced GPU footprint available to a pharmaceutical company.

This computational expansion marks the next phase of a strategic NVIDIA collaboration that started in 2023. By leveraging NVIDIA AI infrastructure, Roche accelerates drug development through high-quality data and groundbreaking AI.

“In healthcare, time is the most critical variable; every day saved means a life-changing medicine or diagnostic reaches a patient sooner,” said Wafaa Mamilli, Roche’s Chief Digital and Technology Officer. “Our AI factory combines world-class computing power with Roche’s scientific expertise to embed AI across the entire value chain — from discovery to development, manufacturing and commercialisation — transforming how we deliver the next generation of medicines and diagnostics solutions.”

Roche’s AI factory is a high-performance supercomputing platform that powers digital transformation across the organisation. In R&D, the NVIDIA BioNeMo platform enhances Roche’s Lab-in-the-Loop, where biological and chemistry experiments are connected with Roche’s AI models. This helps scientists test hypotheses at scale, accelerate progress, and make discoveries that were not possible otherwise. In manufacturing, digital twins — virtual replicas of production lines — powered by NVIDIA Omniverse libraries, allow engineers to optimize processes and factory designs. In diagnostics, accelerated computing and NVIDIA Parabricks software enable insights across vast datasets. In digital pathology, the technologies scan a large number of images to detect subtle disease patterns. In digital health, Roche uses NVIDIA NeMo Guardrails to ensure safe and reliable healthcare-grade conversational AI.

“Our expanded collaboration with NVIDIA and the launch of this AI factory further strengthens our leadership in AI-driven drug discovery and development,” said Aviv Regev, Executive Vice President and Head of Genentech Research and Early Development (gRED). “By providing the massive computational power needed to continue to scale our Lab-in-the-Loop strategy — a space we have pioneered for over five years — our scientists can build more sophisticated predictive frontier models and further shorten the path from biological insight to life-saving medicine.”

Artificial Intelligence at Roche
The implementation of the AI factory is a cornerstone of Roche’s broader digital transformation. For Roche, AI is a key capability designed to augment or complement human expertise. By expanding access to supercomputing capabilities across the organisation, the company empowers its global workforce to tackle the most complex challenges in human disease. Roche’s vision for AI is fundamentally about accelerating the journey toward preventing, stopping, and curing diseases.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Attachment

• Roche Media Release NVIDIA AI factory English

Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions




Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions

• With the addition of 2,176 NVIDIA Blackwell GPUs, Roche now operates the pharmaceutical industry’s largest announced hybrid-cloud AI factory, totaling more than 3,500 GPUs.
• The new computational infrastructure supports Roche’s vision of building an AI-accelerated healthcare organisation.
• NVIDIA AI factories help accelerate discoveries, enable more efficient clinical trials, and unlock data insights at scale, ultimately advancing innovation and improved healthcare outcomes.

Basel, 16 March 2026 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that an expansion of its global AI infrastructure, deploying a large-scale AI factory powered by a full stack of the latest-generation NVIDIA accelerated computing and AI. Featuring 2,176 high-performance GPUs on premises across the United States and Europe and embedded across the entire value chain, this infrastructure is designed to accelerate the development of diagnostics solutions and therapeutics. With this most recent investment, Roche’s combined on-premise and cloud GPU infrastructure now exceeds 3,500 Blackwell GPUs, which is the greatest announced GPU footprint available to a pharmaceutical company.

This computational expansion marks the next phase of a strategic NVIDIA collaboration that started in 2023. By leveraging NVIDIA AI infrastructure, Roche accelerates drug development through high-quality data and groundbreaking AI.

“In healthcare, time is the most critical variable; every day saved means a life-changing medicine or diagnostic reaches a patient sooner,” said Wafaa Mamilli, Roche’s Chief Digital and Technology Officer. “Our AI factory combines world-class computing power with Roche’s scientific expertise to embed AI across the entire value chain — from discovery to development, manufacturing and commercialisation — transforming how we deliver the next generation of medicines and diagnostics solutions.”

Roche’s AI factory is a high-performance supercomputing platform that powers digital transformation across the organisation. In R&D, the NVIDIA BioNeMo platform enhances Roche’s Lab-in-the-Loop, where biological and chemistry experiments are connected with Roche’s AI models. This helps scientists test hypotheses at scale, accelerate progress, and make discoveries that were not possible otherwise. In manufacturing, digital twins — virtual replicas of production lines — powered by NVIDIA Omniverse libraries, allow engineers to optimize processes and factory designs. In diagnostics, accelerated computing and NVIDIA Parabricks software enable insights across vast datasets. In digital pathology, the technologies scan a large number of images to detect subtle disease patterns. In digital health, Roche uses NVIDIA NeMo Guardrails to ensure safe and reliable healthcare-grade conversational AI.

“Our expanded collaboration with NVIDIA and the launch of this AI factory further strengthens our leadership in AI-driven drug discovery and development,” said Aviv Regev, Executive Vice President and Head of Genentech Research and Early Development (gRED). “By providing the massive computational power needed to continue to scale our Lab-in-the-Loop strategy — a space we have pioneered for over five years — our scientists can build more sophisticated predictive frontier models and further shorten the path from biological insight to life-saving medicine.”

Artificial Intelligence at Roche
The implementation of the AI factory is a cornerstone of Roche’s broader digital transformation. For Roche, AI is a key capability designed to augment or complement human expertise. By expanding access to supercomputing capabilities across the organisation, the company empowers its global workforce to tackle the most complex challenges in human disease. Roche’s vision for AI is fundamentally about accelerating the journey toward preventing, stopping, and curing diseases.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Attachment

• Roche Media Release NVIDIA AI factory English

LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC




LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC

Company to Report Fourth Quarter Financial Results and Provide Strategic Update on March 31, 2026

ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) — LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, announced that it reached an agreement with Alcon Research, LLC (“Alcon”) to terminate the merger agreement between the parties.

We understand that the Federal Trade Commission intends to seek to enjoin the acquisition contemplated by the merger agreement. The Company and Alcon mutually agreed that terminating the merger agreement at this time is in the best interest of both companies, as the required closing condition of receiving necessary U.S. regulatory approvals is unlikely to be met by the merger agreement’s outside date of April 23, 2026 or the potential extended outside date of July 23, 2026. The Company will retain the $10.0 million deposit contemplated by the merger agreement.

“While we are disappointed with this outcome and the FTC’s intention to challenge the proposed transaction, we remain committed to advancing the field of cataract surgery through the continued market growth of our ALLY Robotic Cataract Laser System™. Since its commercial introduction in 2022, we believe it has become clearer every day that ALLY is the future of refractive cataract surgery. With ALLY, we were able to significantly extend our technology leadership position, established on the strength of our previous-generation LLS platform. We have expanded our footprint and LENSAR’s influence in the space, which supported market share gains and significant procedure growth. Our team is committed to realizing the full potential of our innovation and capturing the significant untapped opportunity that exists in the market we serve,” said Nick Curtis, President and CEO of LENSAR. “We are focused on continuing to drive the expansion of ALLY’s global installed base and procedure volumes, and creating long-term value for patients, our surgeon partners and shareholders. We will share more detail on our strategy when we release our financial results on March 31, 2026.”

Additional Information:

LENSAR plans to report fourth quarter and full-year 2025 financial results and additional details on its go-forward strategy on Tuesday, March 31, 2026, with a press release to be issued prior to the open of trading. The Company will host a conference call on March 31 at 8:30 a.m. Eastern Time. Details on how to access the conference call will be provided in an upcoming announcement.

About LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary
Streamline® software technology, designed to guide surgeons to achieve better outcomes.

Forward-looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “aim,” “anticipate,” “approach,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “goal,” “intend,” “look,” “may,” “mission,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “should,” “target,” “will,” “would,” or the negative thereof and similar words and expressions.

Forward-looking statements are based on management’s current expectations, beliefs and assumptions and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: (i) risks related to disruption of management time from ongoing business operations due to the terminated merger with Alcon (the “Terminated Merger”); (ii) the risk that any announcements relating to the Terminated Merger could have adverse effects on the market price of the Company’s common stock; (iii) the significant costs, expenses and fees for professional services and other transaction costs in connection with the Terminated Merger and the risk that the deposit from Alcon retained by the Company is insufficient to cover such costs, expenses and fees; (iv) the risk of any litigation related to the Terminated Merger; (v) the risk that the Terminated Merger could have an adverse effect on the ability of the Company to retain and maintain relationships with customers, suppliers and other business partners and retain and hire key personnel and on its operating results and business generally; (vi) the risks inherent in Company’s ability to grow its business; and (vii) the Company’s ability to obtain financing on favorable terms, or at all. In addition, a number of other important factors could cause the Company’s actual future results and other future circumstances to differ materially from those expressed in any forward-looking statements, including but not limited to the other important factors that are disclosed under the heading “Risk Factors” contained in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in its other filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, to be filed with the SEC, each accessible on the SEC’s website at www.sec.gov and the Investor Relations section of the Company’s website at https://ir.lensar.com.

All forward-looking statements are expressly qualified in their entirety by such factors. Except as required by law, the Company undertakes no obligation to publicly update or review any forward-looking statement, whether because of new information, future developments or otherwise. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Source: LENSAR, Inc.

HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update




HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Southlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) — HeartSciences Inc.  (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal third quarter ended January 31, 2026 (“FQ3 2026”) and provided a business update.

Third Quarter and Recent Highlights

During the third quarter and subsequent period, the Company continued advancing the commercialization of its MyoVista Insights™ healthcare IT platform and submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (“FDA”) for 510(k) premarket clearance.

MyoVista Insights™ Healthcare IT Software Platform

• Regulatory classification. MyoVista Insights is classified as a Medical Device Data System (“MDDS”), which carries significantly lower regulatory requirements than medical devices and is exempt from FDA 510(k) clearance. As a result, organizational costs and time to commercial rollout are expected to be substantially lower and faster than those associated with regulated medical devices.

• Platform advancement. Since its early-adopter launch in 2025, the Company has implemented phased upgrades to MyoVista Insights. On March 13, 2026, HeartSciences released a significant version upgrade ahead of the American College of Cardiology (“ACC”) Annual Scientific Session, where the Company will exhibit and publicly introduce the platform to the broader cardiology and healthcare IT community. The upgrade includes mobile phone viewing, reporting enhancements, and significant interoperability improvements designed to support deployment across large health systems.

• Commercial traction. During 2026 the Company’s objectives include establishing key reference sites and generating initial revenues. HeartSciences has already made commercial progress with reference installations and endorsement from a hospital network. Early feedback has been compelling, and the Company is currently in discussions with multiple health systems regarding deployment. Management expects to announce several key customer wins during 2026.

• AI-ECG marketplace opportunity. In addition to generating per-test SaaS revenues as a secure cloud-based ECG data management system, MyoVista Insights is purpose-built to enable the integration of AI-ECG algorithms directly into routine clinical practice through an AI-ECG marketplace. The platform is designed to host third-party algorithms alongside HeartSciences’ own technologies. The Company is currently in discussions with several potential partners to host AI algorithms and believes this model positions HeartSciences to participate in a multi-billion-dollar AI-ECG market opportunity while reducing the cost and time required for algorithm development and regulatory clearance.

• Investor demonstration. Following the public introduction of MyoVista Insights at the ACC Annual Scientific Session, the Company plans to host an investor call to demonstrate the platform and provide additional detail regarding its commercialization strategy and market opportunity.

MyoVista® wavECG™ Device

• The Company submitted its MyoVista wavECG device to the FDA for 510(k) premarket clearance in December 2025.

• HeartSciences elected to separate the FDA submissions for the MyoVista wavECG device and its impaired cardiac relaxation AI-ECG algorithm following updated guidance published by the American Society of Echocardiography (“ASE”) regarding the assessment of Left Ventricular Diastolic Dysfunction (“LVDD”), including revised age-based thresholds for cardiac relaxation (e’).

Management Commentary

Andrew Simpson, Chief Executive Officer of HeartSciences, said, “We are making strong progress toward our 2026 objectives, including establishing reference sites, commencing revenue generation for MyoVista Insights, making AI algorithms available on the platform, and achieving best-in-class interoperability across hospital systems.”

Mr. Simpson added, “The submission of the MyoVista wavECG device to the FDA represents an important regulatory milestone and advances our broader strategy to modernize ECG through the integration of artificial intelligence.”

Fiscal Third Quarter 2026 Financial Results

HeartSciences reported no meaningful revenue for FQ3 2026 as the Company continues to focus on commercialization of the MyoVista Insights platform.

As of January 31, 2026, the Company had approximately $3.4 million in cash and cash equivalents and $2.7 million in shareholders’ equity.

Complete financial results are included in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026, which has been filed with the U.S. Securities and Exchange Commission and is available on the Company’s website at www.heartsciences.com.

About HeartSciences

HeartSciences is a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”). The Company’s MyoVista Insights platform is a device-agnostic, next-generation ECG management system designed to improve clinical efficiency and decision-making. Its MyoVista wavECG device is designed to deliver conventional ECG functionality while supporting on-device AI-enabled solutions.

For more information, please visit: https://www.heartsciences.com. X: @HeartSciences

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company’s future financial and operating performance. All statements, other than statements of historical facts, included herein are “forward-looking statements” including, among other things, statements about HeartSciences’ beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences’ Annual Report on Form 10-K for the fiscal year ended April 30, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 24, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2025 filed with the SEC on September 11, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2025 filed with the SEC on December 15, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026 filed with the SEC on March 16, 2026, and in HeartSciences’ other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Investor Relations:
Integrous Communications
Mark Komonoski, Partner
Phone: 877 255 8483
Email: mkomonoski@integcom.us 

Media Contact:
HeartSciences
Gene Gephart
Phone: +1 682 244 2578 Ext. 2024
Email: info@heartsciences.com

Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock




Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock

CRANFORD, N.J., March 16, 2026 (GLOBE NEWSWIRE) — Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”) today announced that it has extended the expiration date for the exchange offer by the Company to each holder of its Series C Non-Convertible Redeemable Preferred Stock, $0.01 par value per share (the “Series C Preferred Stock”), to exchange such Series C Preferred Stock for shares of Enzon’s common stock, $0.01 par value per share (the “Common Stock”). After giving effect to the extension, the offer expires at 5:00 p.m., Eastern Time, on March 19, 2026, unless the offer is further extended.

Continental Stock Transfer & Trust Company, the depositary for the offer, has advised Enzon that, as of 5:00 p.m., Eastern Time, on March 13, 2026, a total of 342 shares of Series C Preferred Stock had been validly tendered and not properly withdrawn, representing less than 1% of the outstanding shares of Series C Preferred Stock (based on 40,000 shares of Series C Preferred Stock outstanding as of March 13, 2026). Holders of Series C Preferred Stock who have previously validly tendered and not withdrawn their shares do not need to re-tender their shares or take any other action in response to this extension.

Except as described in this press release, the terms of the offer remain the same as set forth in the Prospectus/Consent Solicitation/Offer to Exchange filed with the U.S. Securities and Exchange Commission on January 28, 2026 and declared effective on January 30, 2026 (the “Prospectus/Consent Solicitation/Offer to Exchange”), the letter of transmittal, and the notice of guaranteed delivery.

What’s Being Offered

Enzon is offering all holders of outstanding shares of Series C Preferred Stock the chance to exchange their shares for shares of Common Stock. Each share of Series C Preferred Stock can be exchanged for an amount of Common Stock equal to (i) the aggregate liquidation preference of each share of Series C Preferred Stock, divided by (ii) $7.83 after giving effect to the Reverse Stock Split (as defined in the Prospectus/Consent Solicitation/Offer to Exchange).

Key Dates and Information

• Deadline to Participate: The offer expires at 5:00 p.m., Eastern Time, on March 19, 2026, unless further extended.
• Holders of Series C Preferred Stock who elect to participate in the offer can withdraw their tendered shares any time before the deadline.

Offer Details

The offer is described in full in the Prospectus/Consent Solicitation/Offer to Exchange and the Schedule TO (as defined below), filed with the U.S. Securities and Exchange Commission on January 30, 2026.

• Common Stock Symbol: ENZN (quoted on the “OTCQB” tier of the OTC market)
• Preferred Stock: Not publicly traded; 40,000 shares outstanding as of March 13, 2026

HKL & Co., LLC has been appointed as the Information Agent for the offer, and Continental Stock Transfer & Trust Company has been appointed as the Exchange Agent. Requests for documents should be directed to HKL & Co., LLC at +1 (800) 326-5997 (for individuals) or +1 (212) 468-5380 (for banks and brokers) or via the following email address: enzn@hklco.com.

About Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals, Inc., together with its subsidiary, is positioned as a public company acquisition vehicle that has sought to become an acquisition platform.

For Media Inquiries:

Richard L. Feinstein, CEO and CFO
Email: rlfeinsteincpa@enzon.com

Important Additional Information Has Been Filed with the SEC

The offer commenced on January 30, 2026. On January 28, 2026, a registration statement on Form S-4 and preliminary prospectus included therein was filed with the SEC by the Company, which was declared effective on January 30, 2026, and on January 30, 2026 an exchange offer statement on Schedule TO (the “Schedule TO”), including an offer to exchange, a letter of transmittal and consent and related documents, was filed with the SEC by the Company. The offer to exchange the outstanding shares of Series C Preferred Stock of the Company will only be made pursuant to the Prospectus/Consent Solicitation/Offer to Exchange and Schedule TO, including related documents filed as a part of the offer. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROSPECTUS/CONSENT SOLICITATION/OFFER TO EXCHANGE AND SCHEDULE TO FILED OR TO BE FILED WITH THE SEC CAREFULLY, AS THEY MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND SECURITY HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING THE EXCHANGE OFFER, INCLUDING THE TERMS AND CONDITIONS OF THE EXCHANGE OFFER. Investors and security holders may obtain a free copy of these statements (when available) and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to HKL & Co., LLC at +1 (800) 326-5997 (for individuals) or +1 (212) 468-5380 (for banks and brokers) or via the following email address: enzn@hklco.com. Investors and security holders may also obtain, at no charge, the documents filed or furnished to the SEC by the Company under the “Investors” section of the Company’s website at https://investor.enzon.com/.

No Offer or Solicitation

This press release shall not constitute an offer to exchange or the solicitation of an offer to exchange or the solicitation of an offer to purchase any securities, nor shall there be any exchange or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The offer is being made only through the Schedule TO and Prospectus/Consent Solicitation/Offer to Exchange, and the complete terms and conditions of the offer are set forth in the Schedule TO and Prospectus/Consent Solicitation/Offer to Exchange.

None of the Company, any of its management or its board of directors, or the Information Agent or the Exchange Agent makes any recommendation as to whether or not holders of shares of Series C Preferred Stock should tender shares of Series Preferred Stock for exchange in the offer.

Forward-Looking Statements

Certain statements contained in this filing may be considered forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the proposed transaction involving Enzon and Viskase Companies, Inc. (“Viskase”), the ability to consummate the proposed transaction, the ability to consummate the offer, the timing of the Expiration Date, and the ability to quote the common stock of the combined company on the “OTCQB” tier of the OTC market of the OTC Markets Group, Inc. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: (i) the risk that the conditions to the closing of the proposed transaction are not satisfied, including the failure to obtain the necessary approvals for the proposed transaction; (ii) uncertainties as to the timing of the consummation of the proposed transaction, including timing for satisfaction of the closing conditions, and the ability of each of Enzon and Viskase to consummate the proposed transaction; (iii) the ability of Viskase to timely deliver the financial statements required by the Merger Agreement, as amended; (iv) the possibility that other anticipated benefits of the proposed transaction will not be realized, including without limitation, anticipated revenues, expenses, earnings and other financial results, and growth and expansion of the combined company’s operations, and the anticipated tax treatment of the combination; (v) potential litigation relating to the proposed transaction that could be instituted against Enzon, Viskase or their respective officers or directors; (vi) possible disruptions from the proposed transaction that could harm Enzon’s or Viskase’s respective businesses; (vii) the ability of Viskase to retain, attract and hire key personnel; (viii) potential adverse reactions or changes to relationships with customers, employees, suppliers or other parties resulting from the announcement or completion of the proposed transaction; (ix) potential business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction that could affect Enzon’s or Viskase’s financial performance; (x) certain restrictions during the pendency of the proposed transaction that may impact Enzon’s or Viskase’s ability to pursue certain business opportunities or strategic transactions; (xi) the exchange ratio and relative ownership levels as of the closing of the transactions contemplated by the Merger Agreement, as amended; (xii) estimates regarding future revenue, expenses, and capital requirements following the closing of the transactions contemplated by the Merger Agreement, as amended; (xiii) legislative, regulatory and economic developments; (xiv) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism, trade wars, or outbreak of war or hostilities, as well as management’s response to any of the aforementioned factors; and (xv) such other risks and uncertainties, including those that are set forth in the Registration Statement under the heading “Risk Factors”, in Enzon’s periodic public filings with the SEC, and in Viskase’s annual and quarterly reports posted to Viskase’s website. Enzon and Viskase can give no assurance that the conditions to the proposed transaction will be satisfied. Except as required by applicable law, neither Enzon, nor Viskase undertakes any obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value




Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value

ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) — Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, today announced the successful settlement of its outstanding litigation involving a former Director. This landmark agreement represents a pivotal financial milestone for the Company, delivering immediate and substantial value to current shareholders by improving the capital structure and strengthening the balance sheet.

Under the terms of the settlement, which is expected to close within 30 days, Exousia Pro will make a one-time, strategic payment of $147,500 to the involved parties. In exchange, the Company will secure highly favorable financial restructuring outcomes.

For the purposes of the Company’s upcoming financial reporting and audits, these events will be recorded under Generally Accepted Accounting Principles (GAAP) and will provide the following distinct benefits to the Company and its shareholders:

• Significant Debt Reduction: The settlement triggers the complete cancellation of a $200,000 promissory note issued at closing, as well as the cancellation of the remaining balance on the note tied to the control block of Preferred Stock. Removing these liabilities immediately strengthens Exousia’s balance sheet and frees up future cash flow.
• Reversal of Share Dilution: The agreement secures the cancellation and return to treasury of 6,297,511 shares of Common Stock. Retiring this sizable block of shares reverses prior dilution, directly increasing the equity value, earnings-per-share potential, and ownership percentage of all current shareholders.
• Enhanced Audit Readiness and Transparency: By formally clearing these contested liabilities and equity issuances from the general ledger under GAAP, the Company is positioned for a clean, streamlined audit. This provides greater financial transparency and reinforces confidence within the investment community.

By resolving this legacy dispute efficiently, Exousia Pro’s management team can now focus entirely on advancing its core clinical pipeline and expanding its telehealth initiatives without the distraction or financial overhang of litigation.

About Exousia Pro, Inc. Exousia Pro, Inc. is a biotechnology company at the forefront of exosome research, focused on developing next-generation delivery systems for therapeutic and diagnostic applications. Through its expanding telehealth division, the Company aims to bridge the gap between clinical innovation and patient access.

Forward-Looking Statements This press release contains forward-looking statements regarding the timing of definitive agreements, the closing of the aforementioned settlement, and the expected benefits of financial restructuring and acquisitions. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially from those anticipated.

SAFE HARBOR

Forward-looking statements in this release are made under the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.’s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties’ future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Exousia Pro, Inc.
www.Exousiapro.com
X: @Exousia_Pro

Investor Relations
ir@exousiapro.com